As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene ...

BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...

Request To Download Sample of This Strategic Report @ Rising cases of thyroid cancer is expected to drive the market. According to National Cancer Institute about 1.2% of men and women are detected ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...